{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:12:20Z","timestamp":1785143540469,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1038\/bjc.2011.284","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T20:11:00Z","timestamp":1312315860000},"page":"612-617","source":"Crossref","is-referenced-by-count":70,"title":["Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients"],"prefix":"10.1038","volume":"105","author":[{"given":"A","family":"Carmona-Bayonas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Gonz\u00e1lez-Billalabeitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Canteras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M L","family":"Gonz\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Ayala de la Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,2]]},"reference":[{"key":"BFbjc2011284_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/clinids\/18.1.25","volume":"18","author":"PY Bochud","year":"1994","unstructured":"Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P (1994) Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 18: 25\u201331","journal-title":"Clin Infect Dis"},{"key":"BFbjc2011284_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.2337\/diacare.26.2.516","volume":"26","author":"P Dandona","year":"2003","unstructured":"Dandona P, Aljada A, Bandyopadhyay A (2003) The potential therapeutic role of insulin in acute myocardial infarction in patients admitted to intensive care and in those with unspecified hyperglycemia. Diabetes Care 26: 516\u2013519","journal-title":"Diabetes Care"},{"key":"BFbjc2011284_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/BF01788842","volume":"4","author":"CP Escalante","year":"1996","unstructured":"Escalante CP, Rubenstein EB, Rolston KV (1996) Outpatient antibiotic treatment in low-risk febrile neutropenic cancer patients. Support Care Cancer 4: 358\u2013363","journal-title":"Support Care Cancer"},{"key":"BFbjc2011284_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.1998.16.2.761","volume":"16","author":"JS Groeger","year":"1998","unstructured":"Groeger JS, Lemeshow S, Price K (1998) Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model. J Clin Oncol 16: 761\u2013770","journal-title":"J Clin Oncol"},{"key":"BFbjc2011284_CR5","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1086\/339215","volume":"34","author":"WT Hughes","year":"2002","unstructured":"Hughes WT, Armstrong D, Bodey GP (2002) Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730\u2013751","journal-title":"Clin Infect Dis"},{"key":"BFbjc2011284_CR6","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1002\/cncr.20275","volume":"100","author":"A Jimeno","year":"2004","unstructured":"Jimeno A, Garc\u00eda-Velasco A, del Val O (2004) Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 100: 2462\u20132469","journal-title":"Cancer"},{"key":"BFbjc2011284_CR7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1086\/319207","volume":"32","author":"WV Kern","year":"2001","unstructured":"Kern WV, Heiss M, Steinbach G (2001) Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis 32: 832\u2013835","journal-title":"Clin Infect Dis"},{"key":"BFbjc2011284_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ijantimicag.2007.06.012","volume":"30","author":"J Klastersky","year":"2007","unstructured":"Klastersky J, Ameye L, Maertens J (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30: 51\u201359","journal-title":"Int J Antimicrob Agents"},{"key":"BFbjc2011284_CR9","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1200\/JCO.2005.03.9909","volume":"24","author":"J Klastersky","year":"2006","unstructured":"Klastersky J, Paesmans M, Georgala A (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24: 4129\u20134134","journal-title":"J Clin Oncol"},{"key":"BFbjc2011284_CR10","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18: 3038\u20133051","journal-title":"J Clin Oncol"},{"key":"BFbjc2011284_CR11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1136\/emj.2008.064865","volume":"26","author":"JM Moon","year":"2009","unstructured":"Moon JM, Chun BJ (2009) Predicting the complicated neutropenic fever in the emergency department. Emerg Med J 26: 802\u2013806","journal-title":"Emerg Med J"},{"key":"BFbjc2011284_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/(SICI)1097-0142(19990701)86:1<126::AID-CNCR18>3.0.CO;2-1","volume":"86","author":"CA Mullen","year":"1999","unstructured":"Mullen CA, Petropoulos D, Roberts WM (1999) Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 86: 126\u2013134","journal-title":"Cancer"},{"key":"BFbjc2011284_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s10156-009-0683-Y","volume":"15","author":"Y Nakagawa","year":"2009","unstructured":"Nakagawa Y, Suzuki K, Masaoka T (2009) Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy. J Infect Chemother 15: 174\u2013179","journal-title":"J Infect Chemother"},{"key":"BFbjc2011284_CR14","first-page":"54","volume":"48","author":"HB Nguyen","year":"2006","unstructured":"Nguyen HB, Emanuel PR, Fredrick MA (2006) Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann Emerg Med 48: 54","journal-title":"Ann Emerg Med"},{"key":"BFbjc2011284_CR15","doi-asserted-by":"publisher","first-page":"7437","DOI":"10.1200\/JCO.2004.00.5264","volume":"23","author":"CO Nijhuis","year":"2005","unstructured":"Nijhuis CO, Kamps WA, Daenen SM (2005) Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 23: 7437\u20137444","journal-title":"J Clin Oncol"},{"key":"BFbjc2011284_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/08880010500457673","volume":"23","author":"A Oguz","year":"2006","unstructured":"Oguz A, Karadeniz C, Ckitak EC, Cil V (2006) Which one is a risk factor for chemotherapy-induced febrile neutropenia in childhood solid tumors: early lymphopenia or monocytopenia? Pediatr Hematol Oncol 23: 143\u2013151","journal-title":"Pediatr Hematol Oncol"},{"key":"BFbjc2011284_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1200\/JCO.1996.14.3.919","volume":"14","author":"WR Rackoff","year":"1996","unstructured":"Rackoff WR, Gonin R, Robinson C, Kreissman SG, Breitfeld PB (1996) Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 14: 919\u2013924","journal-title":"J Clin Oncol"},{"key":"BFbjc2011284_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF00365733","volume":"2","author":"F Rossini","year":"1994","unstructured":"Rossini F, Pioltelli P, Mingozzi S (1994) Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors. Support Care Cancer 2: 259\u2013265","journal-title":"Support Care Cancer"},{"key":"BFbjc2011284_CR19","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1002\/1097-0142(19930601)71:11<3640::AID-CNCR2820711128>3.0.CO;2-H","volume":"71","author":"EB Rubenstein","year":"1993","unstructured":"Rubenstein EB, Rolston K, Escalante C (1993) Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71: 3640\u20133646","journal-title":"Cancer"},{"key":"BFbjc2011284_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/jac\/dkf087","volume":"50","author":"MA Sanz","year":"2002","unstructured":"Sanz MA, L\u00f3pez J, Lahuerta JJ (2002) Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 50: 79\u201388","journal-title":"J Antimicrob Chemother"},{"key":"BFbjc2011284_CR21","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/cncr.20890","volume":"103","author":"NV Sipsas","year":"2005","unstructured":"Sipsas NV, Bodey GP, Kontoyiannis DP (2005) Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 103: 1103\u20131113","journal-title":"Cancer"},{"key":"BFbjc2011284_CR22","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1001\/archinte.1988.00380120031007","volume":"148","author":"JA Talcott","year":"1988","unstructured":"Talcott JA, Finberg R, Mayer RJ, Goldman L (1988) The medical course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148: 2561\u20132568","journal-title":"Arch Intern Med"},{"key":"BFbjc2011284_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1200\/JCO.1992.10.2.316","volume":"10","author":"JA Talcott","year":"1992","unstructured":"Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10: 316\u2013322","journal-title":"J Clin Oncol"},{"key":"BFbjc2011284_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1200\/JCO.1994.12.1.107","volume":"12","author":"JA Talcott","year":"2004","unstructured":"Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R (2004) Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12: 107\u2013114","journal-title":"J Clin Oncol"},{"key":"BFbjc2011284_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00520-004-0614-5","volume":"12","author":"A Uys","year":"2004","unstructured":"Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12: 555\u2013560","journal-title":"Support Care Cancer"},{"key":"BFbjc2011284_CR26","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa011300","volume":"345","author":"G Van den Berghe","year":"2001","unstructured":"Van den Berghe G, Wouters P, Weekers F (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345: 1359\u20131367","journal-title":"N Engl J Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2011284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011284","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:02:29Z","timestamp":1684414949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2011284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["BFbjc2011284"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2011.284","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}